Gossamer Bio, Inc. (GOSS): R&D Expense
$174.09M
Year ended 2025-12-31
$163.96M
Trailing 12 months to 2026-06-30
+0.6%
3-year compound annual growth
+1.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $174.09M | +25.7% | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | $138.49M | +2.4% | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | $135.30M | -20.8% | 2026-03-17, From 2023-01-01 |
| 2022-12-31 | $170.92M | +0.4% | 2025-03-13, From 2022-01-01 |
| 2021-12-31 | $170.27M | +5.9% | 2024-03-05, From 2021-01-01 |
| 2020-12-31 | $160.85M | +12.2% | 2023-03-17, From 2020-01-01 |
| 2019-12-31 | $143.40M | +159.4% | 2022-03-03, From 2019-01-01 |
| 2018-12-31 | $55.28M | n/m | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | $891.0K | n/a | 2020-03-24, From 2017-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $174.09M | +25.7% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $61.12M | -27.7% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $159.29M | +15.3% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $97.58M | +49.4% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $197.10M | +54.4% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $17.19M | -15.2% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $5.57M | +15.6% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $56.04M | +36.0% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $19.16M | -60.2% |
Compare GOSS, LXRX, PTGX, SEPN side by side · Screen every company in Pharmaceutical Preparations ↗